An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Phase 3 Trial Results for Lilly’s Oral Weight-Loss Drug, Orforglipron On August 7, Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults...
ENDO 2025 in San Francisco, Calif., is one for the history books! Now it’s time to look ahead to the Society’s other marquee meetings: Clinical Endocrinology Update (CEU) 2025 and Endocrine Board Review (EBR) 2025, both taking place online this fall. Member volunteers and staff have been hard at work preparing these meetings designed primarily... A groundbreaking global international analysis published in eBioMedicine (via The Lancet) has quantified the worldwide cardiovascular toll attributed to di-2-ethylhexyl-phthalate (DEHP) — a common plastic additive used to soften the plastic polyvinyl chloride (PVC), which is found in everyday objects such as vinyl records, pipes, and cosmetics. In 2018 alone, DEHP exposure accounted for an...
Doctors Recreate ‘Mini-Puberty’ to Aid Testicular Development in Male Infants with Rare Disorder
A recent systematic review published in The Journal of Clinical Endocrinology & Metabolism confirms that early hormone therapy can effectively recreate “mini-puberty” in male infants born with congenital hypogonadotropic hypogonadism (CHH) — a rare condition characterized by insufficient hormone production during early infancy. In healthy boys, a temporary surge of hormones shortly after birth —...
Dual Hormone Therapy Boosts Adult Height in Boys with Unexplained Short Stature
By adolescence, most of our adult height is already achieved — only about 15% – 20% remains to be gained. This means that time is of the essence for those with idiopathic short stature (ISS), or children whose height is significantly below the average for their age and sex but without a readily identifiable medical...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves SKYTROFA® for the Once-Weekly Treatment of Adults with GHD On July 28, Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with...
In the arena of endocrine research, high-tech tools are the new power players. In the ever-evolving landscape of endocrinology, the laboratory remains the engine of innovation. From uncovering new hormonal pathways to refining diagnostics and therapeutics, research labs are increasingly dependent on tools that offer speed, sensitivity, and scalability. In the complex environment of endocrine...
Endocrine Society Journal Editors, ENDO 2025 Sessions, and More!
It’s no secret that the Endocrine Society’s peer-reviewed journals are considered the leading research journals in the endocrinology and diabetes space, and this month’s issue highlights a couple of our journal editors who are each making news in very different ways. First off, on the cover we are featuring the next editor-in-chief of Endocrinology, Manuel...
